

Abstract of the Disclosure

This invention relates to the use of T-cadherin polypeptides for screening for modulators thereof, and to the use of said modulators for treating disorders selected from the group consisting of a metabolic disorder, a gynecologic disorder, a chronic
5 inflammatory disorder and a liver or renal disorder. Metabolic disorders that may be treated using a modulator according to the present invention include, *e.g.*, obesity, type II diabetes, insulin resistance, hypercholesterolemia, hyperlipidemia, dyslipidemia, syndrome X, cachexia and anorexia.